PPD Named to InformationWeek 500 List of U.S. Business Technology Innovators

WILMINGTON, N.C., (September 14, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has been named to the 2011 InformationWeek 500, an annual list of the most innovative users of business technology in the United States. The award recognizes PPD's leadership in technology investments, strategies and practices that contribute to effective drug discovery and development programs.

"It's gratifying for InformationWeek to recognize PPD's commitment to advancing technology solutions that enhance the effectiveness of the discovery and development programs our clients have entrusted to us," said Mike Wilkinson, executive vice president and chief information officer of PPD. "Our initiatives strategically drive technology integration with scientific research programs to streamline processes, deliver seamless experiences and increase efficiencies for our clients, employees and patients throughout the endeavor of developing life-changing medicines and therapies."

PPD PatientView empowers clinical trial participants to view, share and electronically archive medical information related to their illnesses, enabling them to play a more active role in managing their health and actively engaging them throughout the duration of a clinical trial. The technology provides the opportunity for greater certainty, enhanced efficiency and improved cost-effectiveness in conducting clinical trials. It is an offering of PPD® Adaptive Solutions, the integrated technology portfolio delivering innovation, speed and cost savings to PPD clients.

The award was presented at a ceremony at the InformationWeek 500 Conference in Dana Point, Calif., on September 13. In PPD's second year being named to the list of the 500 most innovative U.S. business technology leaders, the company cracked the top 100 for the first time, moving up from the top 200 in 2010.

The InformationWeek 500 ranking spotlights the power of innovation in information technology, rather than identifying the biggest IT spenders. InformationWeek tracks the technology, strategies, investments and administrative practices of America's best-known companies. For more information on the InformationWeek 500, visit www.informationweek.com/iw500.

"For 23 years, the InformationWeek 500 has chronicled and honored the most innovative users of business technology," said Rob Preston, editor in chief of InformationWeek. "In this day and age, however, being innovative isn't enough. Companies and their IT organizations need to innovate faster than ever before to stay a step or two ahead of their customers, partners and competitors. This year's ranking placed special emphasis on those high-octane business technology innovators."

Related Content

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD technology solutions, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: rapid technological advances that make our services less competitive; competition in the outsourcing industry; actual operating performance; the ability to attract, integrate and retain key personnel, including a new CEO; risks associated with investments, such as impairments; compliance with drug development regulations; changes in the regulation of the drug development process; the ability to control SG&A spending; overall global economic conditions; economic conditions in the pharmaceutical, biotechnology and government-sponsored research sectors; research and development spending in the pharmaceutical, biotechnology and government-sponsored research sectors; outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in pharmaceutical and biotechnology industries; PPD's ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; fluctuations in currency exchange rates; risks associated with and dependence on strategic relationships; risks associated with fixed price contracts and cost overruns; international economic and political risks; and risks that we may increase, reduce or discontinue our annual dividend policy. These and other PPD risk factors are set forth in more detail from time to time in our SEC filings, copies of which are available free of charge upon request from PPD's investor relations department. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.